3.73
+0.44(+13.37%)
Currency In USD
| Previous Close | 3.29 |
| Open | 3.3 |
| Day High | 3.96 |
| Day Low | 3.29 |
| 52-Week High | 6.33 |
| 52-Week Low | 2.01 |
| Volume | 10.65M |
| Average Volume | 5.37M |
| Market Cap | 560.88M |
| PE | -4.1 |
| EPS | -0.91 |
| Moving Average 50 Days | 3.59 |
| Moving Average 200 Days | 3.09 |
| Change | 0.44 |
If you invested $1000 in Absci Corporation (ABSI) since IPO date, it would be worth $172.77 as of December 04, 2025 at a share price of $3.73. Whereas If you bought $1000 worth of Absci Corporation (ABSI) shares 3 years ago, it would be worth $1,554.17 as of December 04, 2025 at a share price of $3.73.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Absci Announces First Participants Dosed in Phase 1/2a HEADLINE™ Trial of AI-Designed Antibody ABS-201™ for Androgenetic Alopecia
GlobeNewswire Inc.
8 hours ago
Study to evaluate safety and efficacy of novel anti-PRLR antibody; interim data anticipated in the second half of 2026 Trial design leverages operational synergies to enable accelerated registrational trials for androgenetic alopecia (AGA) and Phase
Absci to Report Business Updates and Third Quarter 2025 Financial and Operating Results on November 12, 2025
GlobeNewswire Inc.
Oct 29, 2025 8:05 PM GMT
VANCOUVER, Wash. and NEW YORK, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Absci (Nasdaq: ABSI), a clinical-stage biotech company advancing breakthrough therapeutics with generative AI, today announced the company will report business updates and financial a
Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial
GlobeNewswire Inc.
Oct 15, 2025 12:00 PM GMT
Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership Phase 1/2a trial now expected to begin in December 2025, ahead of prior guidance VANCOUVER, Wash. and NEW YORK, Oct. 15, 2025 (GLOBE NEWSWIRE) -